The biomarker discovery outsourcing service market is estimated to be valued at US$ 13.3 billion in 2024. The biomarker discovery outsourcing service market is predicted to rise at a CAGR of 12.2% from 2024 to 2034. The global biomarker discovery outsourcing service market is anticipated to reach US$ 41.4 billion by 2034.
| Attributes | Key Insights |
|---|---|
| Estimated Market Size in 2024 | US$ 13.3 billion |
| Projected Market Value in 2034 | US$ 41.4 billion |
| Value-based CAGR from 2024 to 2034 | 12.2% |
The increasing research and development activities in the biotechnology and pharmaceutical industries are expected to drive the biomarker discovery outsourcing service market. Outsourcing services are in demand as demand for biomarkers is increasing in the diagnosis and treatment monitoring of various diseases.
With the increasing burden of various chronic diseases such as cancer, neurological disorders, and cardiovascular disorders, the demand for various biomarkers has increased significantly.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2019 to 2023, the biomarker discovery outsourcing service market experienced a CAGR of 15.6%. Increasing advances in technology like bioinformatics, genomics and proteomics, the demand for biomarker discovery outsourcing service are expected to rise.
The biomarkers are primarily utilised in drug development and clinical research applications, the market for outsourcing services is expected to rise. The rising integration of biomarkers in precision medicine drive the demand for outsourcing services tailored to personalized treatment strategies.
The biomarker discovery outsourcing service market is poised for continued expansion with Incresed technological advances and expansion in new therapeutic area. Projections indicate that the global biomarker discovery outsourcing service market will experience a CAGR of 12.2% from 2024 to 2034.
| Historical CAGR from 2019 to 2023 | 15.6% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 12.2% |
Principal Consultant
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The provided table highlights the top five countries in terms of revenue, with the South Korea and Japan leading the list. Incresed regulatory support and funding in biopharmaceutical in South Korea boost the market growth. Biomarker discovery outsourcing service market in Japan is mainly driven by advances in healthcare industry.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 12.4% |
| The United Kingdom | 13.3% |
| China | 12.9% |
| Japan | 13.9% |
| South Korea | 14.0% |
The biomarker discovery outsourcing service market in the United States is expected to expand with a CAGR of 12.4% from 2024 to 2034. Increasing investment in research and development in biopharmaceutical industry driving the market growth.
With the increasing demand for personalized medicines and innovative healthcare solutions, the demand for biomarker discovery outsourcing service is expected to rise in the country.
The increasing advanced in next generation sequencing and bioinformatics accelerated biomarker discovery, providing opportunities for outsourcing services to provide cutting edge solutions to their clients.
The biomarker discovery outsourcing service market in the United Kingdom is expected to expand with a CAGR of 13.3% from 2024 to 2034. The growth of the market in the country is attributed to the presence of robust biotechnology industry.
Increasing government support and funding for biomedical research initiatives drive the demand for outsourcing services. The presence of advanced healthcare infrastructure and increased access to cutting edge technology to boost the market for biomarker discovery outsourcing service in the United Kingdom.
The biomarker discovery outsourcing service market in China is expected to expand with a CAGR of 12.9% from 2024 to 2034. The increasing focus on precision medicines in China contributed to the market growth.
The presence to large patient population and availability of diverse genetic data enhances the quality and relevance of biomarker discovery services in China.
With increasing healthcare innovation and growing demand for customized medicines is increasing, the biomarker discovery outsourcing service market in china will continue to rise during the forecast period.
The biomarker discovery outsourcing service market in Japan is expected to expand with a CAGR of 13.9% from 2024 to 2034.
With the presence of advanced healthcare infrastructure and strong biotechnology sector in Japan, the demand for biomarker discovery outsourcing services for drug discovery and development are expected to rise in the country.
The growing aging population and increased healthcare challenges and various age related disorders such as neurological diseases, cardiovascular disorders, driving the market demand.
Increasing government support and investment in biopharmaceutical industry and Incresed research and development activity are expected to drive the marker discovery outsourcing service market in South Korea.
With the increasing demand for innovative healthcare solutions and precision medicine in South Korea the market for biomarker discovery outsourcing services is expected to rise in the country.
The biomarker discovery outsourcing service market in South Korea is expected to expand with a CAGR of 14% from 2024 to 2034.
The below segment shows the leading segment. Surrogate end-point segment is to rise at a CAGR of 12.0% from 2024 to 2034.Based on type, the genomic biomarker services segment is anticipated to hold a dominant share through 2034. It is set to exhibit a CAGR of 11.8% from 2024 to 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Surrogate End-point | 12.0% |
| Genomic Biomarker Services | 11.8% |
Based on the type, the biomarker discovery outsourcing service market is segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints and other types.
Among these types surrogate end-point segment is anticipated to rise at a CAGR of 12.0% from 2024 to 2034. The demand for surrogate endpoint is high as they provide shorter and cost effective trials.
Surrogate endpoints open up new possibilities for innovation in therapeutic development, as they make it possible to access new treatment more quickly.
Based on the service, the biomarker discovery outsourcing service market is segmented into genomic biomarker services, proteomics biomarker services, bioinformatics biomarker services and other biomarker services. Among these services, genomic biomarker services segment is anticipated to thrive at a CAGR of 11.8 % from 2024 to 2034
Genomic biomarkers are used in early diagnostic and tracking of genetic diseases, infectious diseases and inherited disorders. The increasing reliance on precision medicines driving the high demand for genomic biomarker services.
The market players operation in biomarker discovery outsourcing service market are concentrating on partnership, collaboration, acquisition to gain competitive edge in the market. The leading players are investing in research and development and expansion of service offerings.
Market players are increasing range of service to provide comprehensive biomarker services catering to unique demand of various biotechnology and pharmaceutical clients.
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | US$ 31.1 billion |
| Projected Market Valuation in 2034 | US$ 41.4 billion |
| Value-based CAGR 2024 to 2034 | 12.2% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in US$ billion |
| Key Regions Covered |
|
| Key Market Segments Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
As of 2024, the market for biomarker discovery outsourcing service is expected to be valued at US$ 31.1 billion.
By 2034, the market value of biomarker discovery outsourcing service is expected to reach US$ 41.4 billion.
From 2024 to 2034, the biomarker discovery outsourcing service market is expected to flourish at a CAGR of 12.2%
Surrogate end-point segment is expected to rise at a CAGR of 12% from 2024 to 2034.
South Korea is likely the top-performing market, with a CAGR of 14%.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2024 to 2034
5.3.1. Predictive Biomarkers
5.3.2. Prognostic Biomarkers
5.3.3. Safety Biomarkers
5.3.4. Surrogate Endpoints
5.3.5. Other Types
5.4. Y-o-Y Growth Trend Analysis By Type, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Type, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Service
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Service, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Service, 2024 to 2034
6.3.1. Genomic Biomarker Services
6.3.2. Proteomics Biomarker Services
6.3.3. Bioinformatics Biomarker Services
6.3.4. Other Biomarker Services
6.4. Y-o-Y Growth Trend Analysis By Service, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Service, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2024 to 2034
7.3.1. Oncology
7.3.2. Cardiology
7.3.3. Neurology
7.3.4. Autoimmune Diseases
7.3.5. Other Therapeutic Areas
7.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2024 to 2034
8.3.1. Pharmaceutical Companies
8.3.2. Biotechnology Companies
8.3.3. Other End-Users
8.4. Y-o-Y Growth Trend Analysis By End-User, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By End-User, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Type
10.2.3. By Service
10.2.4. By Therapeutic Area
10.2.5. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Service
10.3.4. By Therapeutic Area
10.3.5. By End-User
10.4. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Type
11.2.3. By Service
11.2.4. By Therapeutic Area
11.2.5. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Service
11.3.4. By Therapeutic Area
11.3.5. By End-User
11.4. Key Takeaways
12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Type
12.2.3. By Service
12.2.4. By Therapeutic Area
12.2.5. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Service
12.3.4. By Therapeutic Area
12.3.5. By End-User
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Type
13.2.3. By Service
13.2.4. By Therapeutic Area
13.2.5. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Service
13.3.4. By Therapeutic Area
13.3.5. By End-User
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Type
14.2.3. By Service
14.2.4. By Therapeutic Area
14.2.5. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Service
14.3.4. By Therapeutic Area
14.3.5. By End-User
14.4. Key Takeaways
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Type
15.2.3. By Service
15.2.4. By Therapeutic Area
15.2.5. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Type
15.3.3. By Service
15.3.4. By Therapeutic Area
15.3.5. By End-User
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Type
16.2.3. By Service
16.2.4. By Therapeutic Area
16.2.5. By End-User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Type
16.3.3. By Service
16.3.4. By Therapeutic Area
16.3.5. By End-User
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Market Share Analysis, 2023
17.1.1.1. By Type
17.1.1.2. By Service
17.1.1.3. By Therapeutic Area
17.1.1.4. By End-User
17.2. Canada
17.2.1. Market Share Analysis, 2023
17.2.1.1. By Type
17.2.1.2. By Service
17.2.1.3. By Therapeutic Area
17.2.1.4. By End-User
17.3. Brazil
17.3.1. Market Share Analysis, 2023
17.3.1.1. By Type
17.3.1.2. By Service
17.3.1.3. By Therapeutic Area
17.3.1.4. By End-User
17.4. Mexico
17.4.1. Market Share Analysis, 2023
17.4.1.1. By Type
17.4.1.2. By Service
17.4.1.3. By Therapeutic Area
17.4.1.4. By End-User
17.5. Germany
17.5.1. Market Share Analysis, 2023
17.5.1.1. By Type
17.5.1.2. By Service
17.5.1.3. By Therapeutic Area
17.5.1.4. By End-User
17.6. UK
17.6.1. Market Share Analysis, 2023
17.6.1.1. By Type
17.6.1.2. By Service
17.6.1.3. By Therapeutic Area
17.6.1.4. By End-User
17.7. France
17.7.1. Market Share Analysis, 2023
17.7.1.1. By Type
17.7.1.2. By Service
17.7.1.3. By Therapeutic Area
17.7.1.4. By End-User
17.8. Spain
17.8.1. Market Share Analysis, 2023
17.8.1.1. By Type
17.8.1.2. By Service
17.8.1.3. By Therapeutic Area
17.8.1.4. By End-User
17.9. Italy
17.9.1. Market Share Analysis, 2023
17.9.1.1. By Type
17.9.1.2. By Service
17.9.1.3. By Therapeutic Area
17.9.1.4. By End-User
17.10. Poland
17.10.1. Market Share Analysis, 2023
17.10.1.1. By Type
17.10.1.2. By Service
17.10.1.3. By Therapeutic Area
17.10.1.4. By End-User
17.11. Russia
17.11.1. Market Share Analysis, 2023
17.11.1.1. By Type
17.11.1.2. By Service
17.11.1.3. By Therapeutic Area
17.11.1.4. By End-User
17.12. Czech Republic
17.12.1. Market Share Analysis, 2023
17.12.1.1. By Type
17.12.1.2. By Service
17.12.1.3. By Therapeutic Area
17.12.1.4. By End-User
17.13. Romania
17.13.1. Market Share Analysis, 2023
17.13.1.1. By Type
17.13.1.2. By Service
17.13.1.3. By Therapeutic Area
17.13.1.4. By End-User
17.14. India
17.14.1. Market Share Analysis, 2023
17.14.1.1. By Type
17.14.1.2. By Service
17.14.1.3. By Therapeutic Area
17.14.1.4. By End-User
17.15. Bangladesh
17.15.1. Market Share Analysis, 2023
17.15.1.1. By Type
17.15.1.2. By Service
17.15.1.3. By Therapeutic Area
17.15.1.4. By End-User
17.16. Australia
17.16.1. Market Share Analysis, 2023
17.16.1.1. By Type
17.16.1.2. By Service
17.16.1.3. By Therapeutic Area
17.16.1.4. By End-User
17.17. New Zealand
17.17.1. Market Share Analysis, 2023
17.17.1.1. By Type
17.17.1.2. By Service
17.17.1.3. By Therapeutic Area
17.17.1.4. By End-User
17.18. China
17.18.1. Market Share Analysis, 2023
17.18.1.1. By Type
17.18.1.2. By Service
17.18.1.3. By Therapeutic Area
17.18.1.4. By End-User
17.19. Japan
17.19.1. Market Share Analysis, 2023
17.19.1.1. By Type
17.19.1.2. By Service
17.19.1.3. By Therapeutic Area
17.19.1.4. By End-User
17.20. South Korea
17.20.1. Market Share Analysis, 2023
17.20.1.1. By Type
17.20.1.2. By Service
17.20.1.3. By Therapeutic Area
17.20.1.4. By End-User
17.21. GCC Countries
17.21.1. Market Share Analysis, 2023
17.21.1.1. By Type
17.21.1.2. By Service
17.21.1.3. By Therapeutic Area
17.21.1.4. By End-User
17.22. South Africa
17.22.1. Market Share Analysis, 2023
17.22.1.1. By Type
17.22.1.2. By Service
17.22.1.3. By Therapeutic Area
17.22.1.4. By End-User
17.23. Israel
17.23.1. Market Share Analysis, 2023
17.23.1.1. By Type
17.23.1.2. By Service
17.23.1.3. By Therapeutic Area
17.23.1.4. By End-User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Type
18.3.3. By Service
18.3.4. By Therapeutic Area
18.3.5. By End-User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Bio-Rad Laboratories, Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Parexel International (MA) Corporation
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Svar Life Science
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Sino Biological, Inc
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. ICON plc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Integrated DNA Technologies, Inc.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Almac Group Limited
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. REPROCELL Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Frontage Labs
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Biomcare ApS
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Crown Bioscience
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Biomarker Discovery Outsourcing Service Market
